| |
April 3-4, 2023 | San Diego, CA The only west coast event exclusively for life science communicators to share best practices, benchmarks, and tools, as well as network with peers. Early Bird Rate Ends January 27th.
|
|
Today's Big NewsJan 26, 2023 |
| By Heather Landi Amazon Pharmacy's RxPass subscription program is not breaking new ground or particularly disruptive to the pharmacy market in the near term. But industry experts say the move is worth watching for how it lays the groundwork for the e-commerce giant's long-term healthcare and pharmacy strategy. |
|
|
|
By Nick Paul Taylor Magenta Therapeutics’ MGTA-117 blood cancer clinical trial has gone from bad to worse. Weeks after Magenta dropped down a dose level in response to serious adverse events (SAEs), a patient has died after receiving the new, lower dose, prompting the biotech to voluntarily pause the study. |
By Kevin Dunleavy Two Bristol Myers Squibb employees who were fired for refusing to be vaccinated against COVID-19 have agreed to settlements, court documents show. A third fired employee who also sued has had her case dismissed. |
By Andrea Park Rockley Photonics, the wearable sensor maker that has formed high-profile partnerships with the likes of Apple and Medtronic, filed for Chapter 11 bankruptcy this week, following months of slipping stock prices and mounting debts. |
|
Thursday, February 16, 2023 | 11am ET / 8am PT Join this session as a panel of experts discusses the realized benefits of using AI and communication tools to redefine the care pathway to detect stroke and streamline the patient journey to direct more patients for cardiology follow-up. Register now.
|
|
By Dave Muoio Deans from the medical schools at Harvard, Columbia, Stanford, UPenn and Mount Sinai said in announcements that the publication's rankings "create perverse incentives" for higher learning institutions. |
By Gabrielle Masson XyloCor Therapeutics’ lead candidate, a one-time gene therapy dubbed XC001, has met both safety and efficacy goals among 28 patients with refractory angina. |
By Annalee Armstrong It’s early days for AC Immune’s Alzheimer’s disease vaccine, but a sneak peek at phase 1b/2 data showed the anti-amyloid beta vaccine elicited a response, allowing it to move up to a higher dose in the trial. |
By Andrea Park Getinge has recalled nearly 8,800 heart devices after receiving more than 100 complaints about them, including one report of a patient death. |
By Fraiser Kansteiner Eyeing potential launches beyond its COVID-19 vaccine Spikevax, Moderna will hire roughly 2,000 new employees in 2023, the company recently told Fierce Pharma. That should bring the biotech’s total headcount to around 6,000 before the year is out, Jerh Collins, Ph.D., Moderna’s chief technical operations and quality officer, said in an interview. |
By Robert King Medicare Advantage plans are bracing for a final risk adjustment rule expected next week that could put them on the hook for overpayments dating all the way back to 2011. |
By Conor Hale The company's Proclaim XR received a new approval from the FDA covering peripheral neuropathy caused by diabetes. |
By Zoey Becker Abortion pill maker GenBioPro filed a lawsuit against West Virginia, claiming that the state's abortion ban violates several laws. |
By James Waldron As an FDA approval decision looms, Sanofi has unveiled more data from a phase 3 trial of its potential hemophilia A rival to Roche’s blockbuster Hemlibra. |
By Fraiser Kansteiner There's been a yearslong will-they or won’t-they situation between England’s cost-effectiveness watchdog and Gilead’s Kite—as well as Novartis—for their respective CAR-T therapies. Now, Gilead has finally gotten the drug cost gatekeeper to warm up to its blood cancer cell therapy. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we take you inside Fierce's JPM Week event. Listen in on snippets from a lively panel discussion on how companies will navigate the drug pricing policies the Biden administration rolled out just last year. And hear from Christine Roth, head of Bayer's oncology strategic business unit, about the company's plans to become a strong competitor in cancer. |
|
|---|
|
|
|
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk and addressing the specific drug supply challenges commonly associated with adaptive, decentralized, platform and other complex trial designs. Register now.
|
|
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
